Open AccessAcetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future
Author(s) -
Brandon Truong,
Jose Paredes Quiroz,
Ronny Priefer
Publication year - 2020
Publication title -
medical research archives
Language(s) - English
Resource type - Journals
eISSN - 2375-1924
pISSN - 2375-1916
DOI - 10.18103/mra.v8i12.2271
Subject(s) - rivastigmine , galantamine , donepezil , acetylcholinesterase , neuroscience , disease , medicine , cognition , cholinergic , alzheimer's disease , dementia , cognitive decline , acetylcholinesterase inhibitor , psychology , pharmacology , biology , biochemistry , enzyme
Alzheimer’s Diseases (AD) is a neurodegenerative disorder characterized by progressive neuronal loss leading to cognitive decline. Although there is yet to be a cure nor a way to reverse the neuronal damage, there are current treatments to amend some of the cognitive symptoms associated with AD. Acetylcholinesterase inhibitors (AChEi) are the primary agents of choice and have had profound implications throughout the past decades. AChEi such as donepezil, rivastigmine, and galantamine mediates and increases cholinergic activities in the central nervous system (CNS), and have been shown to improve and preserve cognition in AD patients. Beyond the current drugs on the market, investigational discoveries continue to explore the potential of safer and more efficacious AChEi agents for the treatment of AD. There have been quite a few challenges, given the high failure rates. Yet, these very trials and studies have been a fundamental step towards better understanding the treatments of AD and have provided some insight on the potential to surpass what is currently available.